SCHEMBL3142607

SCHEMBL3142607

CCC(C)(C)c1ccc(OCC2CO2)c(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
TP53 P04637 3/20 0.48
TSHR P16473 3/20 0.48
MAPT P10636 3/20 0.48
HPGD P15428 2/20 0.48
PPARG P37231 2/20 0.48
HIF1A Q16665 2/20 0.48
CYP1A2 P05177 1/20 0.48
GLA P06280 2/20 0.43
PPARD Q03181 1/20 0.42
PPARA Q07869 1/20 0.42
CYP2C19 P33261 1/20 0.41
VDR P11473 1/20 0.41
SMN1; SMN2 Q16637 4/20 0.39
CYP3A4 P08684 1/20 0.39
ACACB O00763 1/20 0.38
MAPK1 P28482 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10407011 0.87 ALDH1A1 (0.59) ALDH1A1MEN1KMT2ATP53TSHR
SCHEMBL223269 0.82 MRGPRX4 (0.48) ALDH1A1MEN1KMT2ATP53TSHR
SCHEMBL2892222 0.82 MRGPRX4 (0.48) ALDH1A1MEN1KMT2ATP53TSHR
SCHEMBL3142936 0.81 PPARG (0.37) ALDH1A1MEN1KMT2AMAPTPPARG
SCHEMBL3148691 0.77 TP53 (0.73) ALDH1A1MEN1KMT2ATP53TSHR
SCHEMBL7962011 0.76 ALDH1A1 (0.49) ALDH1A1TP53TSHRHPGDHIF1A
SCHEMBL29847389 0.76 ALDH1A1 (0.49) ALDH1A1TP53TSHRHPGDHIF1A
SCHEMBL7962015 0.76 ALDH1A1 (0.49) ALDH1A1TP53TSHRHPGDHIF1A
SCHEMBL2338368 0.76 ALDH1A1 (0.49) ALDH1A1TP53TSHRHPGDHIF1A
SCHEMBL11590720 0.76 ALDH1A1 (0.49) ALDH1A1MEN1KMT2ATP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2137193-B1 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF SANOFI SA (FR) 2017-08-09 EP disclosed
US-8642603-B2 Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof SANOFI (FR) 2014-02-04 US disclosed
US-20100075994-A1 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF SANOFI-AVENTIS (FR) 2010-03-25 US disclosed
EP-2137193-A2 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF Sanofi-Aventis (FR) 2009-12-30 EP disclosed
WO-2008112483-A2 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF SANOFI-AVENTIS (FR) 2008-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075994-A1 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF GRM2, GRM1, GRIN2C ALDH1A1 1875/4885MEN1 3249/4885KMT2A 963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.